聚腺苷酸-聚尿苷酸用于可手术乳腺癌的新型辅助治疗
A new adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer.
作者信息
Lacour F, Lacour J, Spira A, Michelson M, Delage G, Petit J Y, Viguier J
出版信息
Recent Results Cancer Res. 1982;80:200-6. doi: 10.1007/978-3-642-81685-7_32.
Adjuvant treatment with polyadenylic-polyuridylic acid poly A-poly U was tested in 300 patients with operable breast cancer who had all received the same locoregional treatment. They were randomized into two groups; 155 patients receiving 30 mg poly A-poly U i.v. once a week for 6 weeks and 145 controls. Overall survival was significantly improved in the poly A-Poly U group (P less than 0.05). The most striking difference (less than 0.03) was observed in the group of positive node patients, who had a 5-year relapse-free actuarial survival rate of 71% versus 47% in the controls.
对300例可手术乳腺癌患者进行了聚腺苷酸-聚尿苷酸（poly A-poly U）辅助治疗试验，这些患者均接受了相同的局部区域治疗。他们被随机分为两组；155例患者静脉注射30mg聚A-poly U，每周1次，共6周，145例为对照组。聚A-聚U组的总生存率显著提高（P<0.05）。在阳性淋巴结患者组中观察到最显著的差异（<0.03），该组5年无复发生存率为71%，而对照组为47%。
Zotero 插件